Esperion Therapeutics (ESPR) Assets Average (2013 - 2026)

Esperion Therapeutics' Assets Average history runs 14 years deep, the most recent figure standing at $464.2 million for Q1 2026.

• Quarterly Assets Average rose 39.02% year-over-year to $464.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $464.2 million (up 39.02% YoY) and the FY2025 annual result came in at $404.9 million, up 47.32% from the prior year.
• Assets Average was $464.2 million for Q1 2026 at Esperion Therapeutics, up from $415.0 million in the prior quarter.
• Across five years, Assets Average topped out at $464.2 million in Q1 2026 and bottomed at $213.6 million in Q4 2023.
• A 5-year average of $319.3 million and a median of $329.0 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average plunged 31.01% — and 2024, when it soared 54.05%.
• Esperion Therapeutics' Assets Average stood at $280.4 million in 2022, then fell by 23.84% to $213.6 million in 2023, then surged by 54.05% to $329.0 million in 2024, then increased by 26.14% to $415.0 million in 2025, then climbed by 11.87% to $464.2 million in 2026.
• Business Quant data shows ESPR's Assets Average at $464.2 million in Q1 2026, $415.0 million in Q4 2025, and $355.6 million in Q3 2025.